Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
familial amyloid polyneuropathy
Biotech
Hot on Alnylam's heels, AstraZeneca racks up phase 3 ATTR win
AstraZeneca’s $200 million bet on Ionis’ rare disease drug has delivered an early win, teeing up a filing for approval and pursuit of Alnylam.
Nick Paul Taylor
Jun 21, 2022 5:41am
With Pfizer's 'pipeline surprise,' there's a new kid on the ATTR block
Mar 29, 2018 3:31pm
Alnylam plans 2017 filing for new lead patisiran
Jan 11, 2017 8:03am
